AlgoTx Raises €20M to Conduct ATX01's Phase 2 Program in Peripheral Neuropathic Pain

European biotech AlgoTx, the developer of first-in-class treatment ATX01 for chemotherapy-induced peripheral neuropathy (CIPN), announced today the success of a €20M Series B fundraising led by Relyens

Related Keywords

Paris ,France General ,France ,French ,Dennis Riedl ,Bervin Bouani ,Laurent Maillard ,Louis Branger ,Turenne Sant ,Juliette Fontanillas ,Pasteur Mutualit ,Sandra Capela ,Themis Bioscience ,Twitter ,Turenne Group ,Boehringer Ingelheim ,European Investment Fund ,Omnes Foundation ,Health Division Of Turenne Group ,Relyens Innovation Sant ,Turenne Capital ,Investment Director ,Pauline De Breteuil Senior Partner ,Majycc Innovation Sant ,Health Division ,Nord Capital Partenaires ,Paris Based European ,Venture Capital ,Buyout Growth Capital ,Direct Energie ,Omnes Venture Capital ,United Nations Principles ,Responsible Investment ,Cliquet Consultant ,Yanie De Nadaillac ,Algotx ,Raises ,Conduct ,Tx01 ,Hase ,Program ,Peripheral ,Neuropathic ,Rain ,